Biologicals and Biosimilars: Gaps in the Pharmacovigilance System in Portugal
Introduction: Biological and biosimilar medicinal products have specific characteristics that call for a closer monitoring of their safety profile. Since the current legal framework stems from both European and national regulations, some gaps in the operational field may be expected. The goal of thi...
Main Authors: | Maria da Conceição Constantino Portela, Carlos Sinogas, Fernando Albuquerque de Almeida, Ricardo Baptista-Leite, Alexandre Castro-Caldas |
---|---|
Format: | Article |
Language: | English |
Published: |
Ordem dos Médicos
2017-03-01
|
Series: | Acta Médica Portuguesa |
Subjects: | |
Online Access: | http://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8079 |
Similar Items
-
Farmacovigilância em Portugal: Atividade da Unidade Regional do Centro
by: Francisco Batel-Marques, et al.
Published: (2015-04-01) -
Pharmacovigilance in oncology: pattern of spontaneous notifications, incidence of adverse drug reactions and under-reporting
by: Marília Berlofa Visacri, et al.
Published: (2014-04-01) -
O Papel da Farmacovigilância em Contexto da Pandemia por COVID-19
by: Renato Ferreira-da-Silva, et al.
Published: (2021-03-01) -
Retrospectiva de 20 anos de atividade da Unidade de Farmacovigilância do Porto, Portugal
by: Renato Ferreira-da-Silva, et al.
Published: (2021-10-01) -
Farmacovigilância em tuberculose: relato de uma experiência no Brasil
by: Jorge Luiz da Rocha, et al.
Published: (2015-05-01)